NICHOLAS J. VOGELZANG, M.D.                 

 click to view this physician's blog

Click here for full CV

EXPERTISE: Urological Cancers

  • Prostate Cancer
  • Kidney Cancer
  • Bladder Cancer

Chair and Medical Director Developmental Therapeutics and Member GU Committee US Oncology Research Comprehensive Cancer Centers, NV  

ACCOMPLISHMENTS, AWARDS AND HONORS:

  • Schonfeld Memorial Lecture, Kidney Cancer Association 20th Anniversary meeting,Chicago, IL October 1, 2010
  • Keynote Speaker, Japanese Society for Renal Cancer, 40th Anniversary, Tokyo, June 2010
  • Visiting Professor; Juravinski Cancer Center in Hamilton, Ontario, Canada, November 27, 2008
  • Annual award for distinguished volunteer at the Kidney Cancer Association’s Seventh International Kidney Cancer Symposium, Chicago, Illinois, September 2008
  • “Best Doctors of Las Vegas,” by Las Vegas Woman Magazine, October/November 2008
  • ASCO Statesman Award, ASCO Annual Meeting, Chicago, Illinois, June 2007
  • Robert Hart Waldman, MD Lectureship of Medicine and the Visiting Professor, University of Nebraska Medical Center, Omaha, Nebraska, May 2007
  • Health Care Hero in the category of Technology and Research by the Nevada Business Journal, The Four Season, Las Vegas, Nevada, July 31, 2007
  • “52 Best Doctors in the City,” by Las Vegas Life Magazine, June 2005
  • Citizen of Distinction, Foundation for an Independent Tomorrow, March 2005
  • Souther Lecture Series – Providence Hospital, Portland Oregon, 2004
  • “Chicago’s Top Doctors,” Chicago Magazine, January 2004
  • Distinguished Trinity Christian College Alumni, 2003
  • Best Doctors in America, 1994 to present
  • Fred C. Buffett Professorship, University of Chicago, 1999 to 2003
  • Castle Connolly Medical, Ltd., America’s Top Doctors, 2001; Chicago Metro Area, 2001
  • American Cancer Society St. George National Award, 1999
  • Listed in top 500 doctors in Chicago by Chicago Magazine, 1998, 2003, 2005
  • Fellow - American College of Physicians, 1985
  • Gould Foundation Scholar - University of Chicago, 1984
  • American Cancer Society - Junior Faculty Fellowship, 1981 to 1984
  • American Cancer Society - Institutional Research Grant, 1980, 1983
  • American Cancer Society Clinical Fellow, University of Minnesota, 1978 to 1981
  • Resident Award, Flick Family Fund, Rush Medical College, 1976
  • Intern Award, John B. Drake Fund, Rush Medical College, 1975
  • James Scholar, University of Illinois, 1971 to 1974
  • Holstein Memorial Scholarship, Trinity Christian College, 1971
  • National Marine Fisheries Service Research Grant, 1968 to 1970Argonne National Laboratory Student Research Award, 1968 to 1969
  • Top Doctors 2011, Las Vegas Life, Spring 2011: Nicholas J Vogelzang, Research, Oncology – Comprehensive Cancer Centers of Nevada
  • Desert Companion: 159 Best Physicians in Southern Nevada, as Chosen by their Peers: 

PROFESSIONAL EDUCATION & TRAINING:

Oncology Fellowship: Medical Oncology Fellow and Instructor, University of Minnesota, Minneapolis, MN

Residencies: Intern and Resident- Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL. Chief Resident in Medicine and Instructor, Rush Presbyterian St. Luke's Medical Center, Chicago, IL. 

Medical School: M.D. University of Illinois Abraham Lincoln School of Medicine, Chicago, Illinois

Education: B.A. Trinity Christian College, Palos Heights, Illinois

PROFESIONAL/ ACADEMIC APPOINTMENTS:

  • 2009 to present: Chair and Medical Director, Developmental Therapeutic Committee and member Genitourinary and Research Executive Committees, US Oncology Research, Houston, TX 
  • 2009 to present: Medical Oncologist, Comprehensive Cancer Centers of Nevada, Las Vegas, NV
  • 2004 to 2009: Director and Professor, Nevada Cancer Institute, Las Vegas, NV
  • 2008 to 2009: Executive Vice President for Academic Affairs, Nevada Cancer Institute, Las Vegas, NV
  • 2004 to Present: Head of the Genitourinary Oncology and Clinical Professor of Medicine, University of Nevada School of Medicine, Las Vegas/Reno, NV
  • 2000 to 2003: Professor, Ben May Institute for Cancer Research, University of Chicago, Chicago, IL
  • 1999 to 2003: Director, University of Chicago Cancer Research Center, Chicago, IL
  • 1999 to 2003: The Fred C. Buffett Professor of Medicine and Chair in Genitourinary Oncology, University of Chicago, Chicago, IL
  • 1993 to 2003: Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
  • 1993 to 1999: Director of Genitourinary Oncology, University of Chicago, Chicago, IL
  • 1982 to 2003:Member, University of Chicago Cancer Research Center, Chicago, IL
  • 1987 to 1993: Associate Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
  • 1982 to 1987: Assistant Professor of Medicine and Surgery (Urology), University of Chicago, Chicago, IL
  • 1981 to 1982: Assistant Professor of Medicine, University of Minnesota, Minneapolis, MN
  • 1978 to 1981: Medical Oncology Fellow and Instructor, University of Minnesota, Minneapolis, MN
  • 1977 to 1978: Chief Resident in Medicine and Instructor, Rush Presbyterian St. Luke's Medical Center, Chicago, IL
  • 1974 to 1977: Intern and Resident - Internal Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL

BOARD CERTIFICATIONS:

American Board of Internal Medicine: Internal Medicine

American Board of Internal Medicine: Medical Oncology

Diplomat of National Board of Medical Examiners

LOCAL AND NATIONAL COMMITTEES:

 

American Association for Cancer Research (AACR)
  • Cancer Research Editorial Review Board, 1999 to 2002
  • Illinois State Legislative Committee, 1992 to 2004
  • Centennial Celebration Advisory Committee 2005
  • Publication Committee, 2004 to 2006
  • Kidney & Bladder Cancer Research session 2005
  • Targeted Therapy for Renal Cancer Lecture, Anaheim Annual Meeting, 2005
  • Science Policy and Legislative Affairs Committee, 2007 to 2009
American Cancer Society, Illinois Division (ACS)
  • President, 1994 to 1996
  • Immediate Past President, 1996 to 1998
  • First Vice President, 1992 to 1994
  • Second Vice President 1991 to 1992
  • Board of Directors, 1986 to 1998
  • Cancer Incidence and End Results Committee, 1986 to 1997
  • Early Detection Committee, 1996 to 1998
  • Field Service Committee, 1989 to 1991
  • Institutional Grant Review Committee, 1982 to 1994
  • Nominating Committee, 1990 to 1995
  • Professional Education Committee, 1986 to 1996
  • Public Relations Committee, 1986 to 1987
American Cancer Society, National (ACS)
  • Cancer Editorial Advisory Board, 1988 to 2006
  • Detection and Treatment Committee, 1997 to 1998
  • Division Research Workgroup, 1997
  • Host, ACS Excalibur Meeting, Chicago, 2001
  • Medical Affairs Subcommittee on Questionable Methods of Cancer Management Committee, 1994
  • National Board of Directors, 1994 to 1998
  • Organizing Committee for National Conference on New Oncologic Agents, 1991; Prostate Cancer, 1997
  • Prostate Cancer Committee, 1997 to 1999
  • Psychosocial and Behavioral Research Advisory Committee, 1990 to 1991
  • Research & Clinical Investigation Committee, 1994 to 1997
  • Scientific Advisory Committee on Clinical Investigations-IV, 1992
  • Scientific Advisory Committee, 1994 to 1997
American College of Physicians
  • Presenter at Annual Sessions, 1987, 1991, 1992
  • Reviewer for the first Medical Knowledge Self-Assessment Program in the Subspecialty of Oncology (MKSAP - Oncology), 1993
  • Speaker Nevada Chapter ACP January 2009
American Foundation for Urologic Disease, Inc.
  • Prostate Health Council, member, 1997 to 2003

American Society of Clinical Oncology (ASCO)

  • Board of Directors, 1993 to 1996
  • Cancer Communications Committee, 1998, 2009 to present.  Chair-elect 2011
  • Cancer Education Committee, 2003 to 2009
  • Chair, Bladder Cancer Poster Discussion, Annual Meeting, May, 1999
  • Chair, Clinical Science Symposium, Annual Meeting, June, 2007
  • Chairman, Patient Advocacy Committee, 1989 to 1991
  • Discussant, GU Cancers Session, Annual meeting, 2000, 2001, 2004, 2005
  • Discussant, Mesothelioma and Other Uncommon Thoracic Malignancies, Annual Meeting 2004, 2005, 2007
  • Fall Conference, Chicago, IL “Bladder Cancer Tumor Board,” November, 1998
  • JCO Editor Search Committee, 1996
  • Joint ASCO/Blue Cross Blue Shield Technology Evaluation of Prostate Cancer Therapy, 1998
  • Patient Advocacy Committee, Founding Chairperson, 1989 to 1992
  • Program Committee, 1985 to 1986
  • Program Committee, Sub-Chair of GU/Gyn Sessions, 1994 to 1995
  • Program Committee 2003-2005, Sub-Chair of GU Committee 2003-04
  • Best of ASCO lecture, San Francisco, California 2005
  • Prostate Cancer Guideline Committee, 1996 to 2006
  • Public Issues Committee, 1993 to 1996
  • Public Relations Committee, 1987 to 1989
  • Statesman Award, 2007
  • GU Cancer Symposium Faculty Member, 2006, 2008
Association of American Cancer Institutes (AACI)
  • Board of Directors, 2001 to 2004
  • Nevada Cancer Institute Institutional Membership, 2007 to present
  • University of Chicago Institutional Membership, 2000 to 2004
Cancer and Leukemia Group B (CALGB)
  • CALGB Foundation Finance Committee, 1995 to 1999
  • Chemotherapy Committee, 1985 to 1986
  • Data Audit Committee, 1985 to 1990
  • Executive Committee, 1990 to 1993
  • GU Working Group Chair, 1988 to 1993
  • Nominating Committee for New Chairman, 1988 to 1989
  • Principal Investigator (Chicago), 1988 to 1999
  • Prostate/GU Committee Chairman, 1993 to 1999, Member 1999 to 2003
  • Respiratory Committee, 1986 to 1996
  • Vice Chairman Data Audit Committee, 1988 to 1990
  • Cancer Center External Advisory Boards, University of Minnesota 2002-03
  • Winship Cancer Center Emory University, External Advisory Committee for Prostate Cancer, 1996 to 1997
  • Hollings Cancer Center Medical University of South Carolina, 2007 to 2010
  • Cancer Wellness Center, Skokie IL
  • Advisory Board, 1987 to 2004
Center for Biomedical Continuing Education, Chairman:  Paul A. Bunn, Jr., M.D.
  • Board Member, 2000 to 2006
Clinical Care Options Oncology
  • Advisory Board Member 2006 - Present
Department of Defense
  • Data Monitoring Board for the VA Cooperative Study #407, “Prostate Cancer 
  • Intervention versus Observation trial (PIVOT),” 1995 to present
  • Army Prostate Cancer Program, Senior Integration Panel, 1997 to 2005
  • Chair of the Integration Panel, 2003-2004
  • External DOD Advisor PCaP Consortium (J Mohler MD PhD P.I.), 2003 to 2008
  • External DOD Advisor Clinical Trials Consortium (H Scher MD PI) 2003-2010

8th International Congress on Anti-Cancer Treatment

  • Board of Advisors, 1997 to 1999
  • Paris, France, February, 1998
Illinois Cancer Council
  • Co-chairperson, Genito Urinary Committee, 1987 to 1992
International Association for the Study of Lung Cancer
  • Member, 1982 to present
  • Hilton Head, South Carolina, 1982
  • Copenhagen, Denmark, 1985
  • Tokyo, Japan, 1988
  • Barcelona, Spain, 2005
  • San Francisco, CA, 2009

Kidney Cancer Association

  • Founder 1988-89
  • President, 2004 to 2005
  • Board of Trustees, 2002 to 2005
  • Board Member, 1991 to 1996
  • Chairman, Annual Meeting, Chicago, IL, 1998, 2003, 2004
  • Medical Advisory Board, 1990 to 2000, 2010 to present
  • National Volunteer Award, 2008
  • Schonfeld Award 2010
LaGrange Memorial Hospital, La Grange, IL
  • Active Consulting Staff, Department of Medicine, 1987 to 2002
  • Medical Director, LaGrange Treatment Pavilion, 1987 to 1998
Mesothelioma Applied Research Foundation (MARF), Santa Barbara, CA
  • Chairman of the Board, 2006 - 2010
  • Board of Directors, 1999 to present
  • Grant Review Board, 2003, 2004, 2006, 2007, 2008
National Cancer Institute (NCI) Committees
  • Ad Hoc Committee for Selection of Phase I-III Contracts, 1984
  • Ad Hoc Committee for Selection of Urology Research Groups, 1988
  • Ad Hoc Committee for SPORE grants in Prostate Cancer, 1992
  • Ad Hoc Committee for SPORE grants in GU/Lung Cancer, 2005
  • Ad Hoc Review Committee for SPORE Grants in Lung and Lymphoma, 2008
  • Ad Hoc Committee for the General Clinical Research Center, University of Pittsburgh, 5/1993
  • Ad Hoc Advisor for Urology Research, 1988 (CCIRC Meeting -3/88)
  • Co-Chair (with Peter Jones, Ph.D.):  Progress Review Group (PRG) Kidney and Bladder Cancer, 2001-2006
  • Co-editor Kidney/Bladder Cancers Progress Review Group Report, August 2002
  • External Review of laboratory of Molecular Biology (Ira Pastan, MD, P.I.), October 22 – 24, 2007
  • External Review for Promotion of Raffitt Hassan, MD, Principal Investigator, Clinical Cancer Research, NCI
  • Site Visitor, I. David Goldman, M.D., P.I., Albert Einstein Comprehensive Cancer Center, 2001
  • Site Visitor, J. Bertino P0-1 application, Memorial Sloan Kettering Cancer Center, 12/1999
  • Site Visitor, R. Comis, M.D., P.I., Eastern Cooperative Oncology Group, 2001
  • Site Visitor, D. Sugarbaker, PO-1 Application, Dana Farber Harvard Cancer Center, 2004 – 2005
  • Site Visitor, W. Dahut, M.D., P.I., NCI HIV/AIDS Malignancy and Prostate Program, April 20, 2008
  • Special NIH Committee, "Therapeutic Clinical Trials of Malignancies, PAR-95-024," 11/14/1995
  • Special NIH Review Committee, "Therapeutic Clinical Trials of Malignancies, PAR-95-023," 6/71995
  • Study Section H (formerly CCRC) of the NIH/NCI, 1997 to 2002

Nevada Cancer Institute (NVCI) Committees

  • Executive 2004-2009
  • Strategic Performance and Excellence Council (SPEC) 2007- present
  • Medical Oncology Fellowship 2005-present
  • Promotions 2007-present
  • Recruitment 2004-present
  • Continuing Medical Education 2007-present
Pharmaceutical/Oncology Scientific Advisory Boards/ Speakers Bureau
  • Abbott, 2000 to 2003
  • Advanced Life Sciences, 2003
  • Alfacell, 1996 to 2002
  • Allos, 2006
  • Ambit 2008-2010
  • Amgen-Praecis, 1999 to 2000
  • Amgen Denosumab DMSB 2004-2011
  • Anagen, 2002
  • Astrazeneca, 2004
  • Augouron Pharmaceutical, 2000 to 2001
  • Bayer, 2005, 2007, 2008
  • Berlex, Quadramet Educational Advisory Board, 1999
  • Berlex, Leukine Advisory Board, 2005
  • Berlex Pharmaceuticals Prostate Cancer Advisory Board, 2006
  • Corixa, P501 Vaccine, 2004
  • Cougar/ J and J, Abiraterone, 2004 to 2010
  • Dendreon, 1999, 2005, 2010
  • Eli Lilly, 1997 to 2004
  • EXIMIAS Pharmaceutical, 2004
  • EMD/ Merck KGA 2002-2003
  • Genentech, 1998 to 2002
  • Genentech Renal Cell Carcinoma Community Advisory Board, 2009-2010
  • Genta, 2001
  • Glaxo-Wellcome/ GSK, 1997, 2006, 2009-2011
  • Hana Biosciences, 2005
  • HEM, 1991
  • Immunex, 1995 to 1998
  • Janssen, 1996
  • Merck, 2003-2004
  • NaPro, 1999
  • Novartis, 1997, 2001, 2006 to 2011/ Global Speakers Bureau
  • Onyvax, 2005
  • Onyx, 2005 - present
  • Ortho Biotech, 1992 to 1999
  • OSI/Novantrone Prostate Cancer Advisory Board, 2002 to 2005
  • Parke-Davis, 1997
  • Pfizer, 2004 to 2011/ Global Speakers Bureau
  • Pharmacia, 2003
  • Praecis, 2003
  • Rhone-Poulenc-Rorer/Aventis, 1998 to 2002
  • Roche, 1987 to 1995
  • Sanofi Aventis National prostate Cancer Advisory Board 2008-2011
  • Schering Oncology Global Prostate Advisory Board 2006
  • Searle, 1996 to 1998
  • TAP, 1996 to 2002
  • The Prostate Net, 2009
  • Veridex 2008-2011
  • Wilex 2003-2011
  • Wyeth 2007-2010
Rush Medical School
  • Admissions, 1977 to 1978
  • Intern Selection, 1976 to 1977
  • Senior Faculty Evaluation and Promotion, 1977 to 1978
Southwest Oncology Group (SWOG)
  • Member 2006 -present
  • Vice Chair GU Committee, 2007 to Present 
  • GU Translational Medicine Intergroup Committee, 2007 to Present
University of Chicago Cancer Research Center (UCCRC)
  • Director, 1999 to 2003
  • Associate Director Clinical Sciences, 1998 to 1999
  • Cancer Clinical Trials Review Committee, Vice-Chair, 1992 to 1994
  • Member, Executive Committee, 1995 to 2003
  • Program Leader, Prostate Cancer Program, 1995 to 1999
  • Protocol and Data Management Office Faculty Advisory Board, 1997 to 1999
University of Chicago Institutional Committees
  • Dean’s Ad Hoc Advisory Committee, 2003
  • Argonne National Laboratory - Institutional Review Board, 1987 to 1990
  • Chemotherapy Committee, 1982 to 1983
  • Clinical Investigation Committee (IRB), 1983 to 1988
  • Clinical Research Support Office, 2000 to 2002
  • Continuing Medical Education Committee, 1989 to 1994
  • Executive Committee, 1997 to 1999
  • Fellowship Selection Committee, Hematology/Oncology Section, 1983 to 2002
  • Medical Legal Committee, 1993 to 1999
  • Physicians’ Fund Raising Working Group, 1999 to 2001
  • Radioisotope Committee, 1986 to 1988
  • Review Committee for Dermato-Pathology, 2002
  • Search Committees: Chair of the Department of OB/GYN, 2000
  • Ludwig Chair of the Ben May Institute for Cancer Research, 2000 to 2002
  • Knapp Center Director, 1998
  • Working Group on Referring Physician Strategies, 1987 to 1988
University of Minnesota Medical School
  • Admissions, 1979 to 1980
US Too
  • Medical Advisory Board, 2000 to present
  • Scientific Advisory Board, 2000 to present

 

RESEARCH:

1.   Algeta USA (WIRB# 1113976) 10/18/2010
P.I.: Nicholas J. Vogelzang, M.D.
A double-blind, randomised, multipled dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases.
    
2.   Cougar Biotechnology COU-AA-301 03/2010
    P.I.:  Nicholas J. Vogelzang, M.D.
    A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy

3   Cougar Biotechnology COU-AA-302 04/2009
P.I.: Nicholas J. Vogelzang
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients with Metastatic Castration-Resistant Prostate Cancer

4.   Dendreon (IND# BB-IND 6933) 06/29/2010
    A Registry of Sipuleucel-T Therapy in men with advanced prostate Cancer

5.   Tokai (IND# 104,183) TOK – 001, TOK-200-05 09/2009
Phase 1/2., Open label, dose escalation, selected dose comparison trail of TOK-001 for the Treatment of Chemotherapy naïve castration resistant Prostate Cancer